钙黏蛋白相关蛋白及淋巴细胞结合增强因子通过Wnt通路调控G2期阻滞发挥食管癌放射抵抗作用

目的研究淋巴细胞结合增强因子(LEF1)及钙黏蛋白相关蛋白(CTNNB1)的表达与食管癌细胞放射抵抗性的关系并进行机制探讨。方法应用cDNA基因芯片技术筛选食管癌细胞株TE13、KYSE170亲代株和其对应的抵抗株TE13R、KYSE170R在照射前、照射后8h及24h表达差异基因,应用RT-PCR对芯片筛选出的差异基因LEF1及CTNNB1进行验证。应用流式细胞仪分析KYSE170和KYSE170R在照射后24h细胞周期分布的差异。结果综合2对细胞株芯片结果,在接受照射后LEF1及CTNNB1抵抗株较亲代株均有表达上调。RT-PCR结果提示在KYSE170R中CTNNB1在照射后8h,LEF1在照射后24h表达高于KYSE170。KYSE170R在照射后24h发生G2期阻滞较KYSE170更明显。结论 LEF1和CTNNB1可能通过Wnt通路,调控食管癌细胞照射后的G2期阻滞,发挥放射抵抗作用。     

食管癌细胞系TE13R120放射抗性与HDAC3、NF-kB和NRAGE关系的研究

目的探讨HDAC3、NF—kB和NRAGE基因与食管癌细胞放射抗性的关系。方法以人食管癌细胞系TE13和由TE13经γ射线反复照射建立的放射抗性细胞系TE13R120为研究对象，用Western blotting技术检测这两种细胞于不同时间、剂量点照射后基因HDAC3、NF—kB和NRAGE的蛋白表达；用流式细胞术检测相同时间、剂量点两种细胞的凋亡和细胞周期分布情况。结果Western blotting显示，与TE13相比，TE13R120细胞照射前后HDAC3的核表达均增高，NF-kB的表达也明显增强，NRAGE在两种细胞胞浆中的表达无差异。与TE13相比，TE13R120中S期细胞明显增多，照射后G2期阻滞明显，凋亡水平较低。结论基因HDAC3和NF-kB可能在食管癌细胞放射抗性形成中发挥作用并可能有协同作用；NRAGE与食管癌辐射抗性的关系有待进一步研究。     

放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.     

寡转移CRPC原发灶与转移灶全覆盖放疗的疗效和毒性反应分析

目的:探讨原发灶和所有转移灶同时全覆盖放疗治疗寡转移性去势抵抗性前列腺癌(CRPC)的疗效和毒性反应。方法:回顾性分析北京大学第一医院2011年10月至2017年6月收治的44例寡转移(≤4处转移灶)CRPC患者的临床资料。平均年龄72(57~86)岁,初诊时PSA中位值38.545(6.640~1 066.000)n...     

放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.     

黄芪、参芪促肿瘤生长作用的观察

临床上常将一些补益类中药黄芪、人参作为肿瘤治疗的辅助药药 ,其具有调节免疫功能的作用 ,但是近年来有研究报道人参、当归能促进人乳腺癌细胞的增殖生长。本课题旨在观察黄芪注射液、参芪扶正注射液对肿瘤细胞和小鼠肿瘤组织的促生长作用 ,为临床用药提供一些提示。1　材料与     

食管癌放射治疗设定照射野范围的分析研究

目的:分析照射野与预后的关系,为模拟定位时更好地确定照射范围提供参考。方法:回顾分析2000年4月~2001年4月在河北医科大学第四医院放疗科进行后程加速超分割放疗的符合入组条件的食管癌患者102例,计算常规设野时野长和野宽外扩的范围,分析与生存率的关系。结果:常规模拟定位设野长度外扩的范围按照中位值分为≤4·2cm和>4·2cm两组,≤4·2cm组1、2、3和4年生存率分别为76·0%、50·0%、28·3%和21·2%;>4·2cm组分别为69·0%、55·4%、48·2%和38·0%。两组总体生存率差异无统计学意义,χ2=2·15,P=0·14。设野宽度外扩的范围按照中位值分为≤1·8cm和>1·8cm两组,≤1·8cm组1、2、3和4年生存率为64·0%、46·0%、36·0%和29·3%;>1·8cm组为76·9%、53·9%、42·3%和31·5%。两组总体生存率差异无统计学意义,χ2=0·62,P=0·73。结论:设野长度外扩的范围对总体生存率的影响差异无统计学意义,但>4·2cm组在生存方面显示了一定的优越性。设野宽度外扩的范围对总体生存率的影响差异无统计学意义,但>1·8cm组在生存方面显示了一定的优越性。     

利用B型超声影像评价高强度聚焦超声治疗时超声声窗状况的实验研究

目的观察在高强度聚焦超声(HIFU)实验性损伤猪胰腺组织时超声声窗的B型超声影像表现及不同状况下超声声窗上组织损伤情况,对HIFU治疗前超声声窗进行评价。方法对7头家猪进行了HIFU损伤胰腺的实验,并根据HIFU治疗中超声声窗的B型超声影像表现将声窗状况分为"好、中、差"3级。由于评价为"差"的1头猪出现了明显的声窗组织损伤,故暂不进行HIFU治疗,而先行洗胃、排气后重新评价,直至达到"中"以上再行治疗。HIFU治疗结束后观察超声声窗上各组织器官大体损伤情况及病理表现,与治疗前超声声窗影像学分级进行分析,从而得出适合HIFU治疗的声窗评价标准。结果对评价为"差"的1头猪行HIFU治疗后出现腹壁Ⅲ度组织损伤;评价为"中"的1头猪治疗后也出现了声窗上组织损伤,表现为腹壁Ⅱ度烧伤、胃后壁非穿通性溃疡。其余除治疗结束时腹壁有轻度发热外,未发现明显的声窗组织损伤。在各实验动物中均可见到靶目标胰腺的组织学损伤。结论利用B型超声影像评价HIFU超声通道状况具有重要意义。对声窗状况差不可行HIFU治疗者,可采用一定处理方法待评价为"中"或"好"时再进行,评价为"中"者可能出现非靶目标区的损伤,应谨慎进行治疗。     

食管癌后程加速超分割放射合并顺铂治疗的临床研究

目的：探讨同期应用顺铂能否提高后程加速分割（后超）放射治疗食管癌的疗效。方法：对 符合入组条件的81例病例， 随机分为后超组41例[常规分割30Gy＋加速超分割（1．5Gy/次，2次／d)30Gy] 和综合组40例[在后超组基础上静脉输注顺铂（20mg/d、连用5d为1周期、分别在第1、4周实施）共2个周期）。结果：综合组和后超组的1、3年生存率分别为80．0％、73．2％和40．0％、34．2％，但无统计学差异。肿瘤局限在食管壁的病例加用顺铂后生存率提高，综合组和后超组的3年生存率分别为66．7％、25．0％（P＜05）；早、晚期放射反应综合组较后超组高，综合组有3例顽固性咽下疼痛， 反复发作3个月以上。结论：后程加速超分割放射治疗加用顺铂未能明显提高食管癌放射治疗的生存率，但对浸润局限在食管壁的病例能明显提高3年生存率。     

《中华放射肿瘤学杂志》第四届表彰编辑委员名单

由中华放射肿瘤学会主办、河北医科大学第四医院(河北省肿瘤医院)承办的第四届全国食管癌放射治疗研讨会于2005年4月1-3日在石家庄市召开。来自美国德克萨斯M．D．安德森癌症中心张玉蛟博士、日本京都大学光森通英博士和全国近200余位专家学者参加了本次会议。大会开幕式由执行主席万钧教授主持，中华放射肿瘤学会胡逸民教授、河北省医学会理事长李振东教授向大会致辞。河北省肿瘤医院院长王土杰教授、副院长彰俊杰教授到会祝贺。